Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023

Q1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised Sudocetaxel Zendusortide Phase 1 Trial... | April 12, 2023

Related Keywords

United States ,France ,Montreal ,Quebec ,Canada ,French ,American ,America ,Christian Marsolais ,John Leasure ,Elif Mcdonald ,Philippe Dubuc ,Julie Schneiderman ,International Accounting Standards Board ,Scientific Advisory Committee On ,Development Pathway ,Communications Corporate Affairs ,Scientific Advisory Committee ,American Association For Cancer Research ,Company Management Discussion ,International Financial Reporting Standards ,Theratechnologies Inc ,Revenue Grew ,Sudocetaxel Zendusortide ,Guidance Range Confirmed Between ,Commercial Portfolio ,Term Loan Facility ,Marathon Asset ,Marathon Asset Management ,Loan Facility ,Each Marathon Warrant ,Opportunistic Infections ,Cancer Research ,American Association ,Quarter Fiscal ,Interim Financial Statements ,Human Factors Study ,Administrative Expenses ,North America ,Marathon Warrants ,Each Public Offering Warrant ,Chief Executive Officer ,Chief Financial Officer ,Chief Medical Officer ,Global Commercial Officer ,Call Date ,Call Time ,America Dial In ,Access Code ,Forward Looking Statements ,Looking Statements ,Annual Information Form ,Theratechnologies Inc Stock Exchange ,News ,Information ,Press Release ,1 ,023 ,Onsolidated ,Revenue ,Crew ,Upported ,Y ,Grifta ,End ,Growth ,N ,Evised ,Udocetaxel ,Endusortide ,Hase , Th Ca88338h1001 ,